All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Catalyst Pharmaceuticals Inc. turned the commercial corner with FDA approval, on its PDUFA date, of Firdapse (amifampridine phosphate) 10-mg tablets as the first drug designated in the U.S. to treat adults with Lambert-Eaton myasthenic syndrome (LEMS).